Literature DB >> 32158049

An Innovative Immunotherapy Vaccine with Combination Checkpoint Blockade as a First Line Treatment for Glioblastoma in the Context of Current Treatments.

Andrew T Coxon1, Tanner M Johanns1, Gavin P Dunn1.   

Abstract

Glioblastoma is a devastating disease with a dismal prognosis. While recent advancements in cancer immunotherapy have led to improvements in treating other types of cancer, patients with glioblastoma have not benefited from these new therapies and techniques. Fortunately, neurosurgeons and oncologists at Washington University School of Medicine conducting a cutting edge clinical trial are looking to overcome these persistent challenges in treating glioblastoma through combining a personalized vaccine with new immunotherapy drugs. Copyright 2020 by the Missouri State Medical Association.

Entities:  

Year:  2020        PMID： 32158049      PMCID： PMC7023938     

Source DB:  PubMed          Journal:  Mo Med        ISSN： 0026-6620


  37 in total

1.  A point mutation in the alpha-actinin-4 gene generates an antigenic peptide recognized by autologous cytolytic T lymphocytes on a human lung carcinoma.

Authors:  H Echchakir; F Mami-Chouaib; I Vergnon; J F Baurain; V Karanikas; S Chouaib; P G Coulie
Journal:  Cancer Res       Date:  2001-05-15       Impact factor: 12.701

2.  Endogenous Neoantigen-Specific CD8 T Cells Identified in Two Glioblastoma Models Using a Cancer Immunogenomics Approach.

Authors:  Tanner M Johanns; Jeffrey P Ward; Christopher A Miller; Courtney Wilson; Dale K Kobayashi; Diane Bender; Yujie Fu; Anton Alexandrov; Elaine R Mardis; Maxim N Artyomov; Robert D Schreiber; Gavin P Dunn
Journal:  Cancer Immunol Res       Date:  2016-10-31       Impact factor: 11.151

3.  Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma.

Authors:  John H Sampson; Kenneth D Aldape; Gary E Archer; April Coan; Annick Desjardins; Allan H Friedman; Henry S Friedman; Mark R Gilbert; James E Herndon; Roger E McLendon; Duane A Mitchell; David A Reardon; Raymond Sawaya; Robert Schmittling; Weiming Shi; James J Vredenburgh; Darell D Bigner; Amy B Heimberger
Journal:  Neuro Oncol       Date:  2010-12-10       Impact factor: 12.300

4.  PD-1 blockade enhances the vaccination-induced immune response in glioma.

Authors:  Joseph P Antonios; Horacio Soto; Richard G Everson; Joey Orpilla; Diana Moughon; Namjo Shin; Shaina Sedighim; William H Yong; Gang Li; Timothy F Cloughesy; Linda M Liau; Robert M Prins
Journal:  JCI Insight       Date:  2016-07-07

5.  Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas.

Authors:  Jing Zeng; Alfred P See; Jillian Phallen; Christopher M Jackson; Zineb Belcaid; Jacob Ruzevick; Nicholas Durham; Christian Meyer; Timothy J Harris; Emilia Albesiano; Gustavo Pradilla; Eric Ford; John Wong; Hans-Joerg Hammers; Dimitris Mathios; Betty Tyler; Henry Brem; Phuoc T Tran; Drew Pardoll; Charles G Drake; Michael Lim
Journal:  Int J Radiat Oncol Biol Phys       Date:  2013-02-22       Impact factor: 7.038

6.  Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model.

Authors:  David A Reardon; Prafulla C Gokhale; Sarah R Klein; Keith L Ligon; Scott J Rodig; Shakti H Ramkissoon; Kristen L Jones; Amy Saur Conway; Xiaoyun Liao; Jun Zhou; Patrick Y Wen; Annick D Van Den Abbeele; F Stephen Hodi; Lei Qin; Nancy E Kohl; Arlene H Sharpe; Glenn Dranoff; Gordon J Freeman
Journal:  Cancer Immunol Res       Date:  2015-11-06       Impact factor: 11.151

7.  Sequential immunotherapy by vaccination with GM-CSF-expressing glioma cells and CTLA-4 blockade effectively treats established murine intracranial tumors.

Authors:  Pankaj Agarwalla; Zachary Barnard; Peter Fecci; Glenn Dranoff; William T Curry
Journal:  J Immunother       Date:  2012-06       Impact factor: 4.456

8.  Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting.

Authors:  Hirokazu Matsushita; Matthew D Vesely; Daniel C Koboldt; Charles G Rickert; Ravindra Uppaluri; Vincent J Magrini; Cora D Arthur; J Michael White; Yee-Shiuan Chen; Lauren K Shea; Jasreet Hundal; Michael C Wendl; Ryan Demeter; Todd Wylie; James P Allison; Mark J Smyth; Lloyd J Old; Elaine R Mardis; Robert D Schreiber
Journal:  Nature       Date:  2012-02-08       Impact factor: 49.962

9.  Detection of neoantigen-specific T cells following a personalized vaccine in a patient with glioblastoma.

Authors:  Tanner M Johanns; Christopher A Miller; Connor J Liu; Richard J Perrin; Diane Bender; Dale K Kobayashi; Jian L Campian; Michael R Chicoine; Ralph G Dacey; Jiayi Huang; Edward F Fritsch; William E Gillanders; Maxim N Artyomov; Elaine R Mardis; Robert D Schreiber; Gavin P Dunn
Journal:  Oncoimmunology       Date:  2019-01-25       Impact factor: 8.110

10.  Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma.

Authors:  Timothy F Cloughesy; Aaron Y Mochizuki; Joey R Orpilla; Willy Hugo; Alexander H Lee; Tom B Davidson; Anthony C Wang; Benjamin M Ellingson; Julie A Rytlewski; Catherine M Sanders; Eric S Kawaguchi; Lin Du; Gang Li; William H Yong; Sarah C Gaffey; Adam L Cohen; Ingo K Mellinghoff; Eudocia Q Lee; David A Reardon; Barbara J O'Brien; Nicholas A Butowski; Phioanh L Nghiemphu; Jennifer L Clarke; Isabel C Arrillaga-Romany; Howard Colman; Thomas J Kaley; John F de Groot; Linda M Liau; Patrick Y Wen; Robert M Prins
Journal:  Nat Med       Date:  2019-02-11       Impact factor: 53.440
View more
  1 in total

1.  Targeting LAG3/GAL-3 to overcome immunosuppression and enhance anti-tumor immune responses in multiple myeloma.

Authors:  Jooeun Bae; Fabrizio Accardi; Teru Hideshima; Yu-Tzu Tai; Rao Prabhala; Aaron Shambley; Kenneth Wen; Sean Rowell; Paul G Richardson; Nikhil C Munshi; Kenneth C Anderson
Journal:  Leukemia       Date:  2021-07-21       Impact factor: 11.528
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.